Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
No previous study has analyzed the impact of long-term antisecretory drugs on the precision of [13C]urea breath test (UBT). We assessed the rate of UBT conversion from positive to negative results during 60-day therapy with standard doses of ranitidine and pantoprazole. For this purpose, we recruited 60 dyspeptic patients with H. pylori infection ascertained on the basis of the concomitant results of CLO-test, histology, and UBT. Our patients were randomly assigned to receive ranitidine 300 mg at night or pantoprazole 40 mg in the morning for 60 days. UBT was performed at baseline and on days 14, 30, and 60, while patients were still taking antisecretory drugs. Patients with false-negative UBT on day 60 repeated the test every 3 days until conversion. After overnight fasting, duplicate breath test samples were taken from each patient before and 30 min after ingestion of 75 mg [13C]urea dissolved in 150 ml of 0.033 mol/liter citric acid. Four patients dropped out of the study. Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0.5). Afterwards, the three false-negative UBTs in the ranitidine group again became positive during therapy and particularly on day 30 of dosing. Of the four false-negative UBTs in the pantoprazole group at day 60, one became positive after 3 and three after 9 days of therapy cessation. Our findings show that the long-term use of ranitidine and pantoprazole at standard doses has different effects on the results of UBT. In the pantoprazole group patients again became positive within 3-9 days after stopping 60-day therapy, whereas in the ranitidine group patients reverted to positive on day 30 of dosing while they were still on treatment and this was likely due to development of tolerance. Therefore, patients taking pantoprazole need at least a 10-day withdrawal before UBT testing, while those taking ranitidine for at least 30 days can undergo UBT without the necessity of a wash-out period.
Dulbecco
Pietro
P
Dipartimento di Medicina Interna e Specialità Mediche, Università di Genova, Italy.
Gambaro
Camilla
C
Bilardi
Claudio
C
Zentilin
Patrizia
P
Mele
Maria Raffaella
MR
Mansi
Carlo
C
Biagini
Riccardo
R
Tessieri
Laura
L
Iiritano
Elena
E
Usai
Paolo
P
Vigneri
Sergio
S
Savarino
Vincenzo
V
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D001562:Benzimidazoles / Q000008:administration & dosage*; D001944:Breath Tests; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004415:Dyspepsia / Q000188:drug therapy* / Q000382:microbiology; D005188:False Negative Reactions; D005260:Female; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D011446:Prospective Studies; D011899:Ranitidine / Q000008:administration & dosage*; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013454:Sulfoxides / Q000008:administration & dosage*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D013454:Sulfoxides; D011899:Ranitidine; D000077402:Pantoprazole; D009853:Omeprazole